AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Other EventsItem 8.01Other Events.
On May 16, 2018, Audentes Therapeutics, Inc. (the “Company”) issued a press release attached hereto as Exhibit 99.1 announcing interim data from the first dose cohort of ASPIRO, its Phase 1/2 clinical trial. In addition, the Company plans to present the information in the investor presentation attached hereto as Exhibit 99.2 at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held in Chicago, IL on May 16, 2018.
Item 9.01Financial Statements and Exhibits.
|
Exhibit |
|
|
Number |
Description |
|
99.2 |
Investor Presentation (ASGCT). |
Audentes Therapeutics, Inc. ExhibitEX-99.1 2 bold-ex991_7.htm EX-99.1 bold-ex991_7.htm Exhibit 99.1 Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO,…To view the full exhibit click here
About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.